Allogene Therapeutics, Inc. ALLO 深 沪
交易中 10-01 10:18:02 美东时间
1.5601
-0.040
-2.49%
华盛通- 最 高1.61
- 今 开1.60
- 成交量 56.30万股
- 最 低 1.56
- 昨 收 1.60
- 总市值 5.39亿
- 52周最高 4.46
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 1.04
- 委 比 4.02%
- 总股本 3.45亿
- 历史最高 55.00
- 量 比 1.19
- 振 幅 3.13%
- 历史最低 0.8621
- 每 手 1
- 风险率 0.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
Artiva Biotherapeutics will present updated clinical data on 11 Sjögren disease patients treated with AlloNK and rituximab at the 17th International Symposium on Sjögren’s Disease. The oral presentation, titled "AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy, Combined with Rituximab Generates Robust Efficacy Responses in 11 Patients with Sjögren Disease," will be delivered by Guillermo J. Valenzuela, M.D., F.A.C.R., on October 1, 2...
09-23 11:30
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
Fate Therapeutics announced that four abstracts from its off-the-shelf CAR T-cell programs targeting autoimmune diseases will be presented at the ACR Convergence 2026 in Orlando. The presentations cover clinical updates on FT819, including outpatient administration and biomarker associations, as well as preclinical studies on FT839, a dual-CAR T-cell therapy targeting CD19 and CD38. The company emphasizes its commitment to making cell therapy acc...
09-16 11:00
Cellectis Pivots to Gene Editing in Major Overhaul
Cellectis SA (NASDAQ:CLLS) on Monday announced a strategic transformation to become an in vivo gene editing entity focused on long-lasting treatments for chronic diseases. Following the announcement, the stock fell over 27%. The board of directors approved the pivot on September 11, realigning resou...
09-14 21:39
QUICK SPARK: CVC Names TPG’s Todd Sisitsky Co-CEO in Leadership Transition
CVC Capital Partners is bringing in a senior executive from rival TPG as part of a planned leadership transition at the private equity firm. Todd Sisitsky, currently TPG’s president and head of global private equity, will join CVC in the first quarter of 2028 and become co-CEO alongside Peter Rutlan...
09-10 00:09
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
<p>Nkarta, Inc. announced three scientific presentations at ACR Convergence 2026, including two oral presentations on the safety and clinical activity of NKX019 in idiopathic inflammatory myopathy and overall autoimmune indications, and a poster presentation on its activity in systemic sclerosis. NKX019 is an allogeneic, CD19-targeted CAR NK-cell therapy being evaluated in autoimmune diseases. The presentations highlight its safety profile, preli...
09-08 11:00
Allogene Therapeutics Announces Retirement of Chief Financial Officer
Allogene Therapeutics ( ($ALLO) ) has shared an announcement. On August 31, 202...
09-02 21:26
Xtant Medical Enters Exclusive Partnership With Henry Schein's Biohorizons To Distribute The Company's Allogeneic Growth Factor Technology Under The Prolifica Private Brand
The agreement establishes BioHorizons as the exclusive distributor of Xtant's allogeneic growth factor technology into the dental and oral-maxillofacial procedure markets in the United States and Canada, expanding access to the advanced allograft technology for clinicians served by the BioHorizons c...
08-27 20:10
Allogene Therapeutics Signals Progress Amid Key Risks
Allogene Therapeutics (($ALLO)) has held its Q2 earnings call. Read on for the ...
08-23 08:29
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Citizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target
Citizens analyst Reni J. Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Market Outperform and maintains $6 price target.
08-17 20:59
